Bristol Myers Squibb (NYSE:BMY) Stock Unloaded Rep. Julie Johnson

Key Points

• Representative Julie Johnson sold shares of Bristol Myers Squibb for between $1,001 and $15,000 on August 14th, as disclosed in a filing.
• Bristol Myers Squibb's stock traded at $46.22, down by $1.32, with a market cap of $94.08 billion and revenues of $12.27 billion for the last quarter.
• The company recently announced a quarterly dividend of $0.62 per share, representing a 5.4% dividend yield with a payout ratio of 100%.

Representative Julie Johnson (D-Texas) recently sold shares of Bristol Myers Squibb Company NYSE: BMY. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on August 14th. The trade occurred in the Representative's "CHASE BROKERAGE ACCOUNT (3935)" account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Parker-Hannifin NYSE: PH on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 8/14/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Dover NYSE: DOV on 8/14/2025.
• Sold $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/14/2025.

Bristol Myers Squibb Stock Performance

NYSE:BMY traded down $1.32 during trading hours on Friday, reaching $46.22. The company had a trading volume of 11,892,193 shares, compared to its average volume of 9,078,454. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The firm has a market cap of $94.08 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 2.43 and a beta of 0.35. The business's 50 day moving average price is $47.08 and its 200-day moving average price is $50.13. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business's revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. Bristol Myers Squibb's payout ratio is 100.00%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Citigroup decreased their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday, August 1st. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Hold" and an average price target of $56.38.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds have recently added to or reduced their stakes in BMY. Vanguard Group Inc. lifted its holdings in shares of Bristol Myers Squibb by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company's stock valued at $9,023,088,000 after buying an additional 3,522,202 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company's stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC increased its stake in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company's stock valued at $2,132,976,000 after purchasing an additional 723,459 shares in the last quarter. Norges Bank purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $1,554,154,000. Finally, Ameriprise Financial Inc. increased its stake in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company's stock valued at $1,508,099,000 after purchasing an additional 432,158 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.